Cholesterol treatment is not one-size-fits-all. Your age, your 10-year risk of a heart attack or stroke, and any existing health conditions all determine whether you need medication, how aggressively your LDL cholesterol should be lowered, and which treatments are appropriate. A healthy 35-year-old with mildly elevated cholesterol will get a completely different plan than a 60-year-old with diabetes or a 50-year-old who already had a heart attack. Here’s how those decisions break down across the lifespan.
Children and Adolescents: Lifestyle First
For kids, cholesterol treatment almost always starts and stays with diet and exercise. Medication enters the picture only in specific, persistent cases. Statins can be considered for children aged 8 and older, but only when lifestyle changes have failed and a key cholesterol marker (non-HDL cholesterol) stays at or above 145 mg/dL. Even then, statins are typically reserved for children who also have elevated LDL cholesterol, not just high triglycerides alone.
The threshold for more aggressive treatment is high triglycerides that won’t budge. If a child’s triglycerides remain at or above 400 mg/dL despite diet changes and treatment of any underlying condition causing the problem, medication may be warranted. Children with genetic lipid disorders that put them at risk for pancreatitis are the other main group where early drug treatment is considered. For the vast majority of kids with mildly elevated cholesterol, the treatment plan is more vegetables, less sugar, more physical activity, and regular monitoring.
Young Adults (20 to 39): Building a Risk Profile
In your twenties and thirties, cholesterol management is mostly about identifying who’s on a dangerous trajectory rather than prescribing medication right away. Standard risk calculators aren’t designed to estimate 10-year heart attack risk for people under 40 because short-term risk is almost always low at this age, even with elevated cholesterol. That doesn’t mean high LDL is harmless. Cholesterol damage to arteries is cumulative, and decades of exposure matter.
The young adults who do get started on medication early are those with very high LDL levels (often above 190 mg/dL), which can signal familial hypercholesterolemia, a genetic condition affecting about 1 in 250 people. A strong family history of early heart disease, particularly a parent or sibling who had a heart attack before age 55 (men) or 65 (women), also shifts the conversation toward earlier treatment. For most young adults without those red flags, the focus is on establishing healthy habits and getting baseline cholesterol checked so changes can be tracked over time.
Adults 40 to 75: The Core Treatment Window
This is the age range where cholesterol guidelines are most detailed, because it’s when heart attack and stroke risk climbs steeply. Treatment decisions hinge on your estimated 10-year risk of a cardiovascular event, calculated using factors like age, blood pressure, cholesterol levels, smoking status, and diabetes. That score sorts you into one of four categories:
- Low risk (below 5%): Lifestyle changes are the main recommendation. Statins generally aren’t needed.
- Borderline risk (5% to 7.5%): Statins become reasonable if you have risk-enhancing factors like a family history of early heart disease, metabolic syndrome, chronic kidney disease, or inflammatory conditions.
- Intermediate risk (7.5% to 20%): A moderate-intensity statin is typically recommended, with the option to escalate based on individual factors.
- High risk (20% or above): High-intensity statin therapy is recommended to cut LDL cholesterol by at least 50%.
The conversation at borderline and intermediate risk often involves “risk enhancers,” conditions that nudge your actual risk higher than the calculator suggests. These include chronic kidney disease, premature menopause, inflammatory diseases like rheumatoid arthritis, and persistently elevated triglycerides. A coronary artery calcium scan, which measures plaque buildup directly, can also help refine the decision when it’s genuinely uncertain whether medication is worthwhile.
Diabetes Changes the Equation
Diabetes independently accelerates artery damage, so cholesterol treatment is more aggressive for people with this condition. Most adults aged 40 to 75 with diabetes fall into the intermediate or high-risk category, with a 10-year cardiovascular risk of 7.5% or higher. For this group, at minimum a moderate-intensity statin is indicated for primary prevention, meaning even if you haven’t had a heart attack or stroke yet.
If you have diabetes plus additional high-risk conditions, such as established heart disease, chronic kidney disease, or a long duration of poorly controlled blood sugar, the LDL targets get pushed lower and treatment intensity increases. The 2026 ACC/AHA guidelines place people with diabetes and complications in the very high-risk category, with an LDL target below 55 mg/dL. That’s a substantially lower target than the general population, and reaching it often requires adding a second or third medication on top of a statin.
Adults Over 75: A More Individualized Approach
Cholesterol treatment after 75 is one of the least settled areas in cardiology. For older adults who already have heart disease (secondary prevention), continuing statin therapy at moderate intensity is supported by evidence at any age. The benefit of preventing a second heart attack or stroke doesn’t disappear with age.
Starting a statin for the first time after 75 in someone who has never had a cardiovascular event is a different matter. Both American and European guidelines acknowledge that the data on primary prevention in this age group is thin. The major clinical trials that proved statins work enrolled very few patients over 75 and essentially none over 80. As a result, the ACC/AHA, the U.S. Preventive Services Task Force, and the European Society of Cardiology all recommend individualizing the decision rather than making a blanket recommendation. That means weighing factors like overall health, life expectancy, other medications, and personal preferences.
One practical concern in older adults is side effects. Muscle pain and weakness are the most common statin complaints, and older patients may be more susceptible due to reduced muscle mass, kidney function changes, and interactions with other medications they’re taking. For someone who’s been on a statin for years without problems, there’s generally no reason to stop just because they turned 75. But for someone considering a new prescription, the risk-benefit conversation is more nuanced.
Chronic Kidney Disease: Adjusted Dosing
Kidney disease affects how your body processes medications, so cholesterol treatment requires dose adjustments. UK guidelines from NICE recommend starting with atorvastatin 20 mg for adults with chronic kidney disease. The dose can be increased if cholesterol levels don’t respond adequately, but only if kidney filtration (measured by eGFR) is 30 or above. Below that threshold, dose increases aren’t recommended because impaired kidneys can’t clear the medication effectively, raising the risk of side effects.
Chronic kidney disease is also classified as a risk-enhancing factor for cardiovascular events, which means people with kidney disease qualify for statin therapy at lower cholesterol levels than the general population would. This makes sense biologically: kidney disease accelerates the process that hardens and narrows arteries, compounding the damage from elevated cholesterol.
If You Already Have Heart Disease: The Lowest Targets
People who have already had a heart attack, stroke, or been diagnosed with significant artery blockages face the most aggressive cholesterol targets. The 2026 ACC/AHA guidelines set the LDL goal below 70 mg/dL for people with established cardiovascular disease, and below 55 mg/dL for those classified as very high risk.
Very high risk means you’ve had multiple cardiovascular events, or one major event plus additional high-risk conditions. Those conditions include being 65 or older, having diabetes, hypertension, chronic kidney disease, heart failure, a history of smoking, familial hypercholesterolemia, or LDL that remains above 100 mg/dL on maximum statin therapy. If you check several of those boxes, the treatment goal is to push LDL as low as possible.
When statins alone can’t get LDL low enough, the standard approach is a stepwise addition of other medications. The first add-on is typically ezetimibe, which blocks cholesterol absorption in the gut and can lower LDL by an additional 15% to 20%. If that’s still not enough, injectable medications called PCSK9 inhibitors can reduce LDL by another 50% or more. A newer option, bempedoic acid, works through a similar pathway as statins but may be better tolerated by people who experience muscle pain on statins. For those who prefer less frequent dosing, inclisiran is an injectable given just twice a year. The specific combination depends on how far your LDL is from the target and which medications you tolerate well.
What Drives the Differences
The core principle underlying all of these age and condition-specific recommendations is the same: the higher your risk of a cardiovascular event, the lower your LDL target, and the more medications you may need to get there. A low-risk 30-year-old might aim to keep LDL under 130 mg/dL with diet alone. A 55-year-old with diabetes and a prior heart attack needs to get below 55 mg/dL, possibly with three medications working in concert.
Your treatment plan should also evolve over time. Someone who starts with lifestyle changes in their thirties may need a statin by their fifties as risk factors accumulate. Someone on moderate-intensity therapy at 60 may need additional medications after a cardiovascular event at 68. Cholesterol management isn’t a one-time decision. It’s a moving target that shifts as your body and your risk profile change.